Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Giuseppe Bronte, Alessandro Cafaro, Luigi Pasini, Ilaria Priano, Kalliopi Andrikou, Paola Cravero, Marco Angelo Burgio, Angelo Delmonte & Lucio Crinò. (2021) Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy 21:8, pages 809-817.
Read now
Read now
Mohammed Muqtader Ahmed, Farhat Fatima, Md. Khalid Anwer, Mohammed F. Aldawsari, Saurabh Bhatia & Ahmed Al-Harrasi. (2021) Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines. Drug Development and Industrial Pharmacy 47:7, pages 1112-1120.
Read now
Read now
Casmir Turnquist, Robert A Watson, Andrew Protheroe, Clare Verrill & Shivan Sivakumar. (2019) Tumor heterogeneity: does it matter?. Expert Review of Anticancer Therapy 19:10, pages 857-867.
Read now
Read now
G. Hamilton & M.J. Hochmair. (2019) An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 20:13, pages 1551-1561.
Read now
Read now
Articles from other publishers (9)
Rachel S. Kim, Michael K. Nguyen, Kevin R. Card & Carol L. Shields. (2023) Utility of systemic brigatinib therapy in tumour recurrence of choroid metastasis from non–small cell lung carcinoma. Canadian Journal of Ophthalmology.
Crossref
Crossref
Zihui Zhao, Pengfei Li, Yehong Han & Hongyuan Yan. (2023) Honeycomb resin-based spin-column solid-phase extraction for efficient determination of alectinib and its metabolite in human urine. Journal of Chromatography A 1690, pages 463787.
Crossref
Crossref
Mohammad Jahanzeb, Huamao M Lin, Yanyu Wu, Pingkuan Zhang, Magdaliz Gorritz, Catherine B McGuiness, Wei-Ti Huang, Kainan Sun, Chi-Chang Chen & D Ross Camidge. (2022) Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. The Oncologist 27:9, pages 790-798.
Crossref
Crossref
Ao Lu, Yidan Shi, Yijuan Liu, Jiahao Lin, Huarong Zhang, Yating Guo, Lisheng Li, Zeman Lin, Junling Wu, Daihan Ji & Chengdang Wang. (2021) Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma. Lung Cancer 158, pages 29-39.
Crossref
Crossref
Mohd. Imran, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Dhanalekshmi Unnikrishnan Meenakshi, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani, Yahya Mohzari, Ahmed Alrashed, Mohammed AlMotairi, Eman H. Alkhaldi, Abeer K. Alorabi, Ahmed Subeh Alshrari, Mohammad Tauseef, Abida, Saleh I. Alaqel, Ozair Alam & Md. Afroz Bakht. (2021) Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals 14:8, pages 710.
Crossref
Crossref
Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva & Jose Manuel Mas. (2021)
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an
in silico
systems biology-based approach
. Oncotarget 12:4, pages 316-332.
Crossref
Crossref
Ramanathan Karuppasamy, Shanthi Veerappapillai, Sayoni Maiti, Woong-Hee Shin & Daisuke Kihara. (2021) Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer. Seminars in Cancer Biology 68, pages 84-91.
Crossref
Crossref
Mohammed Muqtader Ahmed, Farhat Fatima, Md. Khalid Anwer, Mohammad Javed Ansari, Sabya Sachi Das & Saad M. Alshahrani. (2020) Development and characterization of ethyl cellulose nanosponges for sustained release of brigatinib for the treatment of non-small cell lung cancer. Journal of Polymer Engineering 40:10, pages 823-832.
Crossref
Crossref
Nishant S. Kulkarni, Vineela Parvathaneni, Snehal K. Shukla, Leonard Barasa, Jeanette C. Perron, Sabesan Yoganathan, Aaron Muth & Vivek Gupta. (2019) Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. European Journal of Pharmaceutical Sciences 133, pages 145-159.
Crossref
Crossref